Background
Methods
Procedures
U500R TID (n = 162) | U500R BID (n = 163) |
p value | |
---|---|---|---|
Male, n (%) | 83 (51.2) | 89 (54.6) | .54 |
Race, n (%) | .66b
| ||
White | 133 (82.1) | 133 (81.6) | |
Black | 21 (13.0) | 19 (11.7) | |
Asian | 2 (1.2) | 4 (2.5) | |
Native American | 3 (1.9) | 1 (0.6) | |
Other | 3 (1.9) | 6 (3.7) | |
Ethnicity (Hispanic), n (%) | 32 (19.8) | 30 (18.4) | .76 |
Age, yearsc
| 55.3 ± 10.5 | 55.5 ± 9.0 | .86 |
Weight, kg | 120.9 ± 25.1 | 122.9 ± 26.2 | .48 |
BMI, kg/m2
| 41.8 ± 7.6 | 41.9 ± 7.3 | .95 |
Baseline HbA1c
| 8.7 ± 1.1 | 8.7 ± 1.0 | .87 |
Diabetes duration, years | 14.9 ± 6.8 | 15.5 ± 8.0 | .51 |
TDD, (U-100, final), units | 287.1 ± 79.9 | 287.8 ± 81.2 | .94 |
Number of injections, median [min, max] | .96 |
Measures
Statistical analyses
Results
TRIM-D
TRIM-D Domain | U-500R Treatment (n) | Mean Actual Value (SD) | Change from Baseline (MMRM) LSM (95 % CI)a
| LSM Difference between Treatments (95 % CI) vs. U-500R TIDb
|
---|---|---|---|---|
Overall | ||||
Screening | TID (161) | 60.28 (13.61) | −2.65 (−4.77,−0.53)* | 0.50 (−2.57, 3.56) |
BID (159) | 60.77 (14.27) | −2.53 (−4.67,−0.38)* | ||
Baseline | TID (161) | 61.35 (14.59) | 1.09 (−2.05, 4.22) | |
BID (161) | 62.44 (14.00) | |||
Endpoint | TID (159) | 68.31 (14.14) | 6.04 (3.81, 8.26)** | 3.52 (0.93, 6.11)* |
BID (153) | 72.44 (12.57) | 10.06 (7.82, 12.30)** | ||
Treatment burden | ||||
Screening | TID (160) | 60.37 (18.40) | −2.75 (−6.12, 0.63) | −1.23 (−5.57, 3.11) |
BID (159) | 59.15 (20.91) | −2.63 (−6.01, 0.75) | ||
Baseline | TID (160) | 62.69 (19.39) | − | −2.48 (−6.93, 1.97) |
BID (160) | 60.21 (21.02) | |||
Endpoint | TID (158) | 68.91 (19.31) | 6.23 (2.70, 9.75)* | 5.03 (0.99, 9.06)* |
BID (153) | 72.97 (19.84) | 12.24 (8.71, 15.77)** | ||
Daily life | ||||
Screening | TID (161) | 63.72 (17.38) | −0.72 (−3.77, 2.32) | −0.50 (−4.52, 3.52) |
BID (158) | 63.22 (19.10) | −1.46 (−4.53, 1.62) | ||
Baseline | TID (161) | 62.50 (17.69) | − | 0.97 (−2.95, 4.89) |
BID (161) | 63.47 (18.07) | |||
Endpoint | TID (159) | 66.17 (17.78) | 1.75 (−1.44, 4.93) | 4.01 (0.41, 7.62)* |
BID (153) | 70.63 (17.57) | 6.58 (3.37, 9.79)** | ||
Diabetes management | ||||
Screening | TID (161) | 40.18 (19.53) | −3.71 (−7.07,−0.35)* | 4.27 (−0.15, 8.69) |
BID (158) | 44.45 (20.62) | 0.13 (−3.26, 3.52) | ||
Baseline | TID (161) | 43.15 (20.83) | − | 0.91 (−3.67, 5.49) |
BID (161) | 44.07 (20.95) | |||
Endpoint | TID (159) | 57.02 (18.92) | 13.40 (9.89, 16.92)** | 0.52 (−3.62, 4.65) |
BID (153) | 57.87 (19.75) | 14.89 (11.35, 18.43)** | ||
Compliance | ||||
Screening | TID (161) | 65.06 (17.34) | −3.04 (−5.79,−0.29)* | 1.24 (−2.64, 5.11) |
BID (158) | 66.30 (17.84) | −2.58 (−5.37, 0.22) | ||
Baseline | TID (161) | 67.43 (17.09) | − | 2.02 (−1.76, 5.79) |
BID (161) | 69.45 (17.33) | |||
Endpoint | TID (159) | 73.00 (16.87) | 5.31 (2.43, 8.19)** | 4.48 (1.50, 7.47)* |
BID (153) | 78.12 (14.52) | 9.89 (6.98, 12.80)** | ||
Psychological health | ||||
Screening | TID (161) | 68.09 (19.17) | −2.90 (−5.67,−0.13)* | −0.14 (−4.36, 4.08) |
BID (159) | 67.95 (19.20) | −5.00 (−7.80,−2.20)** | ||
Baseline | TID (161) | 68.02 (19.07) | − | 3.49 (−0.50, 7.47) |
BID (161) | 71.51 (17.23) | |||
Endpoint | TID (159) | 73.90 (19.86) | 4.57 (1.66, 7.47)* | 3.22 (−0.11, 6.56) |
BID (153) | 79.49 (16.00) | 7.50 (4.58, 10.43)** |
TRIM-D Domain | Reduced Number of Injections | U-500R Treatment (n) | Mean Value (SD) | Change from Baseline | LSM Change from Baseline (SE) |
---|---|---|---|---|---|
Overall | 0–2 | TID (121) | 67.78 (14.60) | 5.74 (13.98) | 6.15 (1.08)* |
BID (58) | 72.73 (12.56) | 7.95 (13.37) | 10.51 (1.60)* | ||
3–4 | TID (36) | 70.54 (12.39) | 11.32 (15.78) | 8.48 (2.02)* | |
BID (85) | 72.06 (12.89) | 10.83 (13.71) | 9.86 (1.29)* | ||
>4 | TID (2) | 59.82 (16.41) | 3.57 (6.31) | −1.22 (8.31) | |
BID (10) | 74.02 (10.65) | 10.27 (10.88) | 9.89 (3.79)* | ||
Treatment burden | 0–2 | TID (120) | 68.65 (19.77) | 5.36 (21.62) | 7.09 (1.69)* |
BID (58) | 70.62 (21.93) | 9.55 (25.43) | 10.84 (2.47)* | ||
3–4 | TID (36) | 70.37 (18.06) | 8.91 (21.92) | 6.61 (3.14)* | |
BID (85) | 74.59 (18.91) | 15.08 (21.02) | 12.78 (2.00)* | ||
>4 | TID (2) | 58.33 (17.68) | 0.00 (11.79) | −3.42 (12.90) | |
BID (10) | 72.92 (14.33) | 9.58 (19.35) | 10.17 (5.89) | ||
Daily life | 0–2 | TID (121) | 65.51 (18.76) | 2.24 (19.05) | 2.61 (1.50) |
BID (58) | 72.52 (17.34) | 7.61 (19.99) | 8.85 (2.22)* | ||
3–4 | TID (36) | 68.89 (14.40) | 9.17 (17.42) | 6.75 (2.81)* | |
BID (85) | 69.24 (17.33) | 7.18 (19.02) | 6.68 (1.79)* | ||
>4 | TID (2) | 57.50 (3.54) | −7.50 (10.61) | −8.59 (11.54) | |
BID (10) | 71.50 (21.61) | 4.00 (16.12) | 5.46 (5.27) | ||
Diabetes management | 0–2 | TID (121) | 56.46 (19.32) | 12.33 (23.57) | 12.95 (1.72)* |
BID (58) | 57.74 (20.00) | 9.63 (24.48) | 14.09 (2.55)* | ||
3–4 | TID (36) | 59.44 (17.92) | 19.83 (27.95) | 15.08 (3.23)* | |
BID (85) | 58.18 (20.15) | 15.29 (25.55) | 13.87 (2.06)* | ||
>4 | TID (2) | 47.50 (10.61) | 12.50 (17.68) | 5.38 (13.29) | |
BID (10) | 56.00 (16.30) | 15.00 (16.83) | 12.38 (6.06)* | ||
Compliance | 0–2 | TID (121) | 72.47 (17.61) | 4.17 (15.47) | 4.27 (1.24)* |
BID (58) | 77.51 (15.30) | 8.76 (14.30) | 9.77 (1.84)* | ||
3–4 | TID (36) | 75.00 (14.56) | 9.72 (22.43) | 7.34 (2.33)* | |
BID (85) | 78.09 (14.26) | 9.12 (14.96) | 9.16 (1.48)* | ||
>4 | TID (2) | 68.75 (8.84) | 3.13 (13.26) | 0.13 (9.58) | |
BID (10) | 81.88 (12.66) | 7.50 (13.44) | 9.27 (4.37)* | ||
Psychological health | 0–2 | TID (121) | 73.30 (20.56) | 4.76 (17.85) | 4.45 (1.38)* |
BID (58) | 81.51 (15.17) | 5.60 (13.69) | 9.39 (2.06)* | ||
3–4 | TID (36) | 76.39 (17.12) | 9.98 (15.79) | 7.53 (2.59)* | |
BID (85) | 77.61 (16.86) | 8.01 (18.10) | 7.28 (1.65)* | ||
>4 | TID (2) | 65.63 (30.94) | 7.81 (2.21) | 0.78 (10.68) | |
BID (10) | 83.75 (11.39) | 13.13 (13.24) | 11.32 (4.86)* |
U-500R TID (n = 159) n (%) | U-500R BID (n = 153) n (%) | Total (N = 312) n (%) | Odds Ratio U-500R BID/TID | 95 % CI of Odds Ratio |
p-value | |
---|---|---|---|---|---|---|
Number of patients with TRIM-D compliance score ≥80 | 58 (36.5) | 75 (49.0) | 133 (42.6) | 1.70 | 1.05, 2.75 | .03 |
EQ-5D-5L
EQ-5D-5L US Index - Visit | U-500R Treatment (n) | LSM (SE) |
p-value Visit Comparison (Change from Baseline)a
| LSM Difference (95 % CI) vs. U-500R TID |
---|---|---|---|---|
Screening | TID (161) | 0.77 (0.01) | 0.97 | 0.01 (−0.02, 0.04) |
BID (158) | 0.78 (0.01) | 0.35 | ||
Baseline | TID (162) | – | 0.00 (−0.03, 0.03) | |
BID (161) | – | |||
Endpoint | TID (159) | −0.02 (0.01) | 0.30 | 0.01 (−0.02, 0.03) |
BID (152) | −0.01 (0.01) | 0.80 |